Guidelines for HIV post-exposure prophylaxis: web annex A: summaries of declarations of interest

Guidelines for HIV post-exposure prophylaxis Web Annex A. Summaries of declarations of interest © World Health Organization 2024 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. Web annex A. Summaries of declarations of interest. In: Guidelines for HIV post-exposure prophylaxis. Geneva: World Health Organization; 2024. https://doi.org/10.2471/B09091. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/. Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-orders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication forms part of the WHO guideline entitled Guidelines for HIV post-exposure prophylaxis. It is being made publicly available for transparency purposes and information, in accordance with the WHO handbook for guideline development, 2nd edition (2014). Design and layout by Lushomo. 1Composition of Guideline Development Group (GDG) Region Percentage African 29% Americas 24% Eastern Mediterranean 6% European 6% South East Asia 6% Western Pacific 29% Gender Percentage Female 65% Male 29% Transgender woman 6% Transgender man 0 2 Guidelines for HIV Post-Exposure Prophylaxis – Web Annex A Types of interests reported by GDG members Name 1. Employment and consulting 2. Research support 3. Investments & 4. Business interests 5. Public statements and positions 6. Additional information 7. Tobacco products Conflicts and management plan Euphemia Sibanda (co-chair) 0 2a. Funding (grant) – I am PI of a study evaluating peer-led implementation of HIV testing and prevention services, including PEP – CeSHHAR Zimbabwe – Research Unit – $116,994 – Current 2a. Funding (grant) – I am PI of a study evaluating peer-led implementation of HIV testing and prevention services, including PEP – CeSHHAR Zimbabwe-Research Unit-GBP£1,895,007 – Starting Oct 2023 0 0 0 0 Financial not significant Full participation Iskandar Azwa 0 0 0 0 0 0 Full participation Manisha Dhakal 0 0 0 0 0 0 Full participation Lina Digolo 0 0 0 0 0 0 Full participation Lv Fan 0 0 0 0 0 0 Full participation Julie Fox 0 0 0 0 0 0 Full participation Kim Green 0 Donor funding for PrEP research (USAID) – PATH – no – $200,000 – no 0 0 0 0 Financial not significant Full participation Beatriz Grinystejn 0 0 0 0 0 0 Full participation Nathalie Kapp 0 0 0 0 0 0 Full participation Jules Kim 0 0 0 0 0 0 Full participation 3Name 1. Employment and consulting 2. Research support 3. Investments & 4. Business interests 5. Public statements and positions 6. Additional information 7. Tobacco products Conflicts and management plan Kudzai Maingire 0 0 0 5a) I have attended District AIDS Action Committee (DAAC) meetings in Seke district whilst I was on attachment as a trainee health promotion officer. As part of HIV/AIDS prevention task force, I emphasized the need to raise awareness on the use of PEP amongst our free community leadership and students. I also dream of the realisation of the Zim Agenda 2030 of ending AIDS and achieving epidemic control through engaging multilevel stakeholders and them on the importance of using PEP among at risk populations 0 0 Full participation Mohammed Majam *1a) Employment 0 0 0 0 0 Full participation Kenneth Meyer 0 Research grant (PEP) – Gilead Sciences – institution where I work – $261,166 – 2020; Research grant (PrEP) – Merck, Inc – institution where I work – $539,453 – Current; Research grant (PEP) – Gilead Sciences – institution where I work – $499,922 – Current 0 0 0 0 Financial not significant Full participation Njambi Njuguna 0 0 0 0 0 0 Full participation Danvic Rosadino 0 0 0 0 0 0 Full participation Hasna Salem 0 0 0 0 0 0 Full participation Darrell Tan 2a. Abbvie – My institution – $198,000 CAD – 2021; 2a. Gilead – My institution – $530,000 CAD – current; 2a. GSK – My institution – $260,000 CAD – current 0 0 0 0 Financial significant Partial participation Excluded from evidence to decision making and formulating recommendations related to task sharing for PEP delivery 4 Guidelines for HIV Post-Exposure Prophylaxis – Web Annex A External Review Group Conflicts management: The steering group assessed comments for validity on a case-by-case basis, in the context of the reviewer’s conflict of interests. Name 1. Employment, consulting & technical advisory boards 2. Research support 3. Investments & 4. Business interests 5. Public Statements statements and positions 6. Additional information 7. Tobacco products Chris Akolo 0 0 0 0 0 0 Judy Auerbach Consulting fees – Bill & Melinda Gates Foundation – US$ 96 000 – 2024 0 0 0 0 0 Teddy Cook 0 0 0 0 0 0 Frances Cowan 0 0 0 0 0 0 Rashida Ferrand 0 0 0 0 0 0 Morgan Garcia 0 0 0 0 0 0 Bridget Haire 0 0 0 0 0 0 Diane Havlir 0 ViiV provides CAB LA for an NIH funded research project where I am the principal investigator. I receive no funding from ViiV; the study is fully funded by NIH 0 0 0 0 Mehdi Karkouri 0 0 0 0 0 0 Colleen Kelley 0 Research grant to my institution – Gilead Sciences and ViiV – Grants to conduct clinical trials of new PrEP modalities 0 0 0 0 Jeff Lucas 0 0 0 0 0 0 Sheena McCormack 0 2a Grants to support paediatric clinical trials – ViiV, Gilead – Employer – No idea – these are not my trials – Ongoing 0 5b Guideline writing group member – BHIVA/BASHH – N/A – N/A – N/A; 5b Scientific Advisory Board member – MATRIX (Magee Women’s Institute) – MRC CTU at UCL – US$2500 per meeting to UCL – Ongoing 0 0 5Name 1. Employment, consulting & technical advisory boards 2. Research support 3. Investments & 4. Business interests 5. Public Statements statements and positions 6. Additional information 7. Tobacco products Saiqa Mullick 0 Wits RHI is awaiting a potential drug donation of CAB-LA from drug developer for a planned implementation science study. Wits RHI has also been involved in the clinical trials of CAB-LA; however, funding was not received directly from the product developer. Wits RHI runs various clinical trials (where Saiqa Mullick is not a PI) with multiple donors but no profit is made from any of these trials/projects. 0 0 0 0 Will Nutland BHIVA/BASHH – Me – Nil – 2024; ViiV – Me – Nil – 2024 – For BHIVA/BASHH – providing pro-bono consultation on UK national PrEP clinical guidelines. For ViiV – pro-bono participation in community consultation on long -acting injectable PrEP. NB: no income was generated from this (my non-profit has a policy of not accepting money from pharma) 0 0 0 0 0 Nittaya Phanuphak Consulting –- ViiV Healthcare – institution – US$1244 – 2022 – 2023 Research grant – Gilead Sciences – Institution – US$94,195 – 2022 – 2023 0 0 0 0 Andrew Philips 0 0 0 0 0 0 Kristine Torjesen 0 0 0 0 0 0 Francois Venter 0 I am on international and local guideline committees but make no commercial selection decisions. 0 0 0 0 For more information, contact: World Health Organization Global HIV, Hepatitis and STIs Programmes 20, Avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int https://www.who.int/health-topics/hiv-aids